Advertisement

Topics

LIDDS signs license agreement for prostate cancer drug Liproca® Depot with major Chinese pharma company

10:40 EDT 16 May 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
UPPSALA, SWEDEN - LIDDS AB (publ) has signed a license agreement for Liproca® Depot with Jiangsu Ambition Medical, a Chinese pharmaceutical company specializing in global collaborations and in-licensing. Liproca® Depot is L...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "LIDDS signs license agreement for prostate cancer drug Liproca® Depot with major Chinese pharma company"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...